PEDIATRICS Vol. 91 No. 5 May 1993, pp. 859-866
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Javitt, J.
Right arrow Articles by Chiang, Y.-p.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Javitt, J.
Right arrow Articles by Chiang, Y.-p.

Cost-Effectiveness of Screening and Cryotherapy for Threshold Retinopathy of Prematurity

Jonathan Javitt MD, MPH1, Ronald Dei Cas MD1, and Yen-pin Chiang PhD1

1 From the Worthen Center for Eye Care Research, Center for Sight, Georgetown University Medical Center, Washington, DC.

Background. Retinopathy of prematurity (ROP) is the leading cause of blindness among premature infants. A recent National Eye Institute-sponsored prospective, multicenter trial investigating the use of cryotherapy for treatment of ROP demonstrates a significant reduction in blindness and low vision for patients with sight-threatening (stage 3+) ROP.

Method. A microsimulation model is presented to determine the cost-effectiveness of cryotherapy for ROP. Simulations are performed for three subpopulations of premature infants with birth weights 500 through 749 g, 750 through 999 g, and 1000 through 1249 g, and for three screening strategies—weekly, biweekly, and monthly.

Results. Appropriately timed screening for and treatment of ROP is predicted to result in a gain of 3899 to 4648 quality-adjusted-life-years and a net governmental budgetary savings of $38.3 to $64.9 million for each annual US birth cohort of 28 321 premature infants (500 through 1249 g). The cost per quality-adjusted-life-year gained is $2488 to $6045, depending on different screening strategies.

Conclusions. Of greatest importance is the finding that properly timed screening and treatment for ROP is not only cost saving but may save approximately 320 infants per year from a lifetime of blindness.

Key Words: retinopathy of prematurity • cryotherapy • cost-effectiveness • Monte Carlo simulation

Submitted on August 12, 1992
Accepted on December 18, 1992




This article has been cited by other articles:


Home page
 Arch OphthalmolHome page
K. M. Jackson, K. E. Scott, J. Graff Zivin, D. A. Bateman, J. T. Flynn, J. D. Keenan, and M. F. Chiang
Cost-Utility Analysis of Telemedicine and Ophthalmoscopy for Retinopathy of Prematurity Management
Arch Ophthalmol, April 1, 2008; 126(4): 493 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
M. F. Chiang, J. D. Keenan, J. Starren, Y. E. Du, W. M. Schiff, G. R. Barile, J. Li, R. A. Johnson, D. J. Hess, and J. T. Flynn
Accuracy and reliability of remote retinopathy of prematurity diagnosis.
Arch Ophthalmol, March 1, 2006; 124(3): 322 - 327.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
I. Griebsch, J. Coast, and J. Brown
Quality-Adjusted Life-Years Lack Quality in Pediatric Care: A Critical Review of Published Cost-Utility Studies in Child Health
Pediatrics, May 1, 2005; 115(5): e600 - e614.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. C. Angus, G. Clermont, R. S. Watson, W. T. Linde-Zwirble, R. H. Clark, and M. S. Roberts
Cost-Effectiveness of Inhaled Nitric Oxide in the Treatment of Neonatal Respiratory Failure in the United States
Pediatrics, December 1, 2003; 112(6): 1351 - 1360.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
J. D. Reynolds, V. Dobson, G. E. Quinn, A. R. Fielder, E. A. Palmer, R. A. Saunders, R. J. Hardy, D. L. Phelps, J. D. Baker, M. T. Trese, et al.
Evidence-Based Screening Criteria for Retinopathy of Prematurity: Natural History Data From the CRYO-ROP and LIGHT-ROP Studies
Arch Ophthalmol, November 1, 2002; 120(11): 1470 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
G E Quinn
What do you do about ROP screening in "big" babies?
Br. J. Ophthalmol., October 1, 2002; 86(10): 1072 - 1073.
[Full Text]

Home page
 Arch Pediatr Adolesc MedHome page
S. K. Lee, C. Normand, D. McMillan, A. Ohlsson, M. Vincer, C. Lyons, and for the Canadian Neonatal Network
Evidence for Changing Guidelines for Routine Screening for Retinopathy of Prematurity
Arch Pediatr Adolesc Med, March 1, 2001; 155(3): 387 - 395.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. C. Brown, M. M. Brown, S. Sharma, W. Tasman, and H. C. Brown
Cost-Effectiveness of Treatment for Threshold Retinopathy of Prematurity
Pediatrics, October 1, 1999; 104(4): 47e - 47.
[Abstract] [Full Text]

Home page
 PediatricsHome page
S. E. Brooks, D. M. Marcus, D. Gillis, E. Pirie, C.{s. M. H. Johnson, and J. Bhatia
The Effect of Blood Transfusion Protocol on Retinopathy of Prematurity: A Prospective, Randomized Study
Pediatrics, September 1, 1999; 104(3): 514 - 518.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
K. Wright, M. E. Anderson, E. Walker, and V. Lorch
Should Fewer Premature Infants Be Screened for Retinopathy of Prematurity in the Managed Care Era?
Pediatrics, July 1, 1998; 102(1): 31 - 34.
[Abstract] [Full Text]

Home page
 Med Decis MakingHome page
J. Lipscomb, M. Ancukiewicz, G. Parmigiani, V. Hasselblad, G. Samsa, and D. B. Matchar
Predicting the Cost of Illness: A Comparison of Alternative Models Applied to Stroke
Med Decis Making, April 1, 1998; 18(2): S39 - S56.
[Abstract] [PDF]